Nucleic Acid Detection Immunoassay for Prostate-Specific Antigen Based on Immuno-PCR Methodology | Zendy

Jonathan E. McDermed | Zendy; Ron Sanders | Zendy; Stephen Fait | Zendy; Robert E. Klem | Zendy; Mark Sarno | Zendy; Thomas H. Adams | Zendy; Eleftherios P. Diamandis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nucleic Acid Detection Immunoassay for Prostate-Specific Antigen Based on Immuno-PCR Methodology

Author(s) -

Jonathan E. McDermed,

Ron Sanders,

Stephen Fait,

Robert E. Klem,

Mark Sarno,

Thomas H. Adams,

Eleftherios P. Diamandis

Publication year - 2012

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/clinchem.2011.170290

Subject(s) - prostate specific antigen , immunoassay , prostate cancer , detection limit , chromatography , urology , chemistry , antigen , medicine , prostate , prostatectomy , cancer , antibody , immunology

Serum prostate-specific antigen (PSA) concentrations after radical prostatectomy typically become undetectable with the use of current immunometric assay methods. Despite modern surgical techniques, 15%-30% of prostate cancer patients undergoing radical prostatectomy develop a biochemical recurrence during follow-up. Unfortunately, poor analytical sensitivity of standard PSA assays delays biochemical recurrence detection, and because of day-to-day assay imprecision ultrasensitive PSA assays cannot assess PSA kinetics. We developed an immuno-PCR assay for total PSA that has a limit of quantification >10 times lower than current ultrasensitive assays.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research